Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 13/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 13/20 | 0.73 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.64 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6519315 | 1.00 | P2RY6 (0.73) | P2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL16805438 | 0.89 | P2RY6 (0.75) | P2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL18858918 | 0.89 | P2RY6 (0.75) | P2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL19411923 | 0.89 | P2RY6 (0.75) | P2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL18871314 | 0.89 | P2RY6 (0.75) | P2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL18852574 | 0.89 | P2RY6 (0.75) | P2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL17211412 | 0.89 | P2RY6 (0.75) | P2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL2133591 | 0.88 | P2RY6 (0.75) | P2RY6P2RY2P2RY4DNPH1 | |
| SCHEMBL12714923 | 0.88 | P2RY6 (0.75) | P2RY6P2RY2P2RY4DNPH1 | |
| Thymidine_Triphosphate SCHEMBL3502894 | 0.88 | P2RY6 (0.73) | P2RY6P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050003371-A1 | Modified nucleotides and methods of labeling nucleic acids | STRATAGENE | 2005-01-06 | — | — | US | disclosed |
| WO-2004037989-A2 | MODIFIED NUCLEOTIDES AND METHODS OF LABELING NUCLEIC ACIDS | STRATAGENE (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050003371-A1 | Modified nucleotides and methods of labeling nucleic acids | RNGTT, NT5C3B, NT5E | P2RY6 214/4885P2RY2 408/4885P2RY4 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.